Amplia Therapeutics Limited (ASX: ATX) - Share Price

Current share price for ATX : $0.125 0.005 (4.17%)⁺

Amplia Therapeutics Limited (ATX) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company has a development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a role in chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

ATX General Information ⁺

ASX Code	ATX
Website	N/A
Industry/Sector	Biotechnology
Market Cap ($M)	64
ATX Share Price	$0.125
Day High	$0.125
Day Low	$0.120
Last Close	$0.120
ATX Share Price Movement	$0.01 ( 4.17% )

Prices as at 16:30, 17 Sep 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Amplia Therapeutics Limited (ATX) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Amplia Therapeutics Limited (ATX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Amplia Therapeutics Limited (ATX) price-sensitive announcements

ATX - Amplia signs Collaboration and Supply Agreement with Lilly

Amplia Therapeutics Limited has entered into a Clinical Trial Collaboration and Supply Agr

Amplia Therapeutics Limited (ATX)
4 Aug 2026 | 8:22 AM

ATX - Quarterly Activities/Appendix 4C Cash Flow Report

Amplia Therapeutics Limited reported significant progress in its cancer treatment programs

Amplia Therapeutics Limited (ATX)
29 Jul 2026 | 8:29 AM

ATX - Preliminary Final Report and Annual Report YE 31 March 2026

Amplia Therapeutics Limited's financial report for the year ending 31 March 2026, highligh

Amplia Therapeutics Limited (ATX)
29 May 2026 | 1:37 PM

ATX - Amplia Launches First Stage of Pivotal Narmafotinib Trial

Amplia Therapeutics Limited has announced the initiation of a Phase 2b clinical trial for

Amplia Therapeutics Limited (ATX)
19 May 2026 | 8:18 AM

Amplia Therapeutics Limited (ATX) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Amplia Therapeutics Limited (ATX) ORDINARY FULLY PAID	Health Care	$64	Amplia Presents at E&P Healthcare Conference 2026	16 Sep 2026 3:05PM	$0.125	$0.125	fallen by 0%
Amplia Therapeutics Limited (ATX) ORDINARY FULLY PAID	Health Care	$64	Amplia and ANZGOG Finalise Protocol for Ovarian Cancer Trial	15 Sep 2026 8:21AM	$0.120	$0.125	risen by 4.17%
Amplia Therapeutics Limited (ATX) ORDINARY FULLY PAID	Health Care	$64	Notification regarding unquoted securities - ATX	9 Sep 2026 5:24PM	$0.130	$0.125	fallen by 3.85%
Amplia Therapeutics Limited (ATX) ORDINARY FULLY PAID	Health Care	$64	Results of Annual General Meeting	28 Aug 2026 12:10PM	$0.148	$0.125	fallen by 15.25%
Amplia Therapeutics Limited (ATX) ORDINARY FULLY PAID	Health Care	$64	CEO Managing Director Presentation to Annual General Meeting	28 Aug 2026 9:38AM	$0.150	$0.125	fallen by 16.67%
Amplia Therapeutics Limited (ATX) ORDINARY FULLY PAID	Health Care	$64	Bioshares Biotech Summit Presentation	6 Aug 2026 10:09AM	$0.160	$0.125	fallen by 21.88%

ATX Financial Summary

Year to Mar	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2026A	-$7.71	-$1.60	-23.40%	0.00%	0.0%
2025A	-$6.57	-$2.10	-3.20%	0.00%	0.0%
2024A	-$4.50	-$2.20	-28.00%	0.00%	0.0%

ATX Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2024 A	2025 A	2026 A	2024 A	2025 A	2026 A	2024 A	2025 A	2026 A
Amplia Therapeutics Limited (ATX)	$62M	-0.2336	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
CSL Limited (CSL)	$83,625M	0.7309	-0.4438	0.0545	10.7958	19.4097	18.4057	2.44%	2.39%	2.47%
Clinuvel Pharmaceuticals Limited (CUV)	$422M	-0.0696	-0.0719	0.0242	12.5150	13.4839	13.1654	0.60%	0.60%	0.60%
Mesoblast Limited (MSB)	$2,675M	-0.4380	0.0000	0.0000	0.0000	0.0000	326.9841	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$6,031M	-1.3893	0.0000	-0.9100	0.0000	170.0192	1,888.2979	0.00%	0.00%	0.00%

ATX Directors

Name	Position	Start Date
Dr Christopher John Burns	Chief Executive Officer, Managing Director	4 May 2018
Mr Andrew John Cooke	Company Secretary	1 Jan 0001
Dr Robert Peach	Non-Executive Director	2 Sep 2015
Dr Warwick Bonner Tong	Non-Executive Director	4 May 2018
Mr Brett Anthony Carter	Non-Executive Director	6 Jul 2026
Ms Jane Catherine Bell	Non-Executive Director, Non-Executive Chairman	12 Apr 2021

Amplia Therapeutics Limited (ATX) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
1 Sep 2025	BELL, Jane	Issued	Indirect Shares	130,435	$0.230	$30,000.050
1 Sep 2025	TONG, Warwick	Issued	Indirect Shares	152,174	$0.230	$35,000.020
1 Sep 2025	BURNS, Christopher	Issued	Direct Shares	86,957	$0.230	$20,000.110

See all changes in directors' interest & trades for Amplia Therapeutics Limited (ATX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

ATX Management

Name	Position
Hamish George	Chief Financial Officer
Jason Lickliter	Chief Medical Officer

ATX Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Amplia Therapeutics Limited (ATX). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
45,313,932 (9.31%)	Platinum Investment Management Limited
36,144,321 (7.43%)	Acorn Capital Limited

ATX Calendar of Events

Date	Event
28 May 2027	Report (Annual)
28 May 2027	Report (Prelim)
26 November 2026	Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us